EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Women’s health Imprimer
In the Science. 2010 Jul 19.issue, Karim et al [Epub ahead of print]) present results of the effectiveness and safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women, a double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445) with placebo gel (n = 444) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 /100 women-years, compared to 9.1 per 100 women-years in the placebo gel arm. In high adherers (>80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate and low adherers, the HIV incidence reduction was 38% and 28%, respectively. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use.


SHARING-OBGYN is a service that I intend to share with you. The idea is to send one short email message a day concerning an article that appeared recently and might be of interest to you.
The selection of the articles is arbitrary, but there are no commercial interests involved and no conflict of interest.
If you want to be removed from the list of persons to whom these emails are sent please let me know.
If you want to bring comments or add email addresses of friends or colleagues, please feel free to do so.

 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн